Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Emerging Technologies for Diagnostics & Liquid Biopsies - New Orleans 2024

Emerging Technologies for Diagnostics & Liquid Biopsies - New Orleans 2024 Agenda


Print Agenda

Thursday, 26 September 2024

00:00

John McDevittKeynote Presentation

Title to be Confirmed.
John McDevitt, Chair, Department Biomaterials, New York University College of Dentistry Bioengineering Institute, United States of America

00:00

Daniel ChiuKeynote Presentation

New Fluorescent Reagents to Enable Highly Multiplexed Cellular Measurements
Daniel Chiu, A. Bruce Montgomery Professor of Chemistry, University of Washington, United States of America

Fluorescence based techniques have become an indispensible tool kit in both basic cellular studies and in vitro diagnostics. However, the intrinsic limitations of conventional dyes, such as short Stoke’s shift and low absorptivity, have posed difficulties for advancing highly multiplexed assays. We have developed a new class of fluorescent probes called Pdots, and this talk will highlight their development and performance to enable highly multiplexed fluorescence measurements in diagnostics.

00:00

Lydia SohnKeynote Presentation

Title to be Confirmed
Lydia Sohn, Almy C. Maynard and Agnes Offield Maynard Chair in Mechanical Engineering, University of California-Berkeley, United States of America

00:00

Tony HuKeynote Presentation

EV-based Omics Analysis Enabling Personalized Diagnosis
Tony Hu, Professor and Weatherhead Presidential Chair, Tulane University School of Medicine, United States of America

Diagnostics for infectious and malignant diseases often exhibit poor specificity/sensitivity, hindering early detection and treatment evaluation, but development of improved assays is limited by several challenges, including absence of disease-specific factors, low biomarker concentrations, and interfering factors. We have employed an array of sensitive analytic technology platforms to identify key host-pathogen interactions that influence pathogenesis and applies this information to identify diagnostic and predictive biomarkers that can be applied for personalized medicine to improve patient outcomes. We reported the development and validation of several nanotechnoloy-based assays platforms that can be used to quantify protein and nucleic acid changes in EV-associated protein biomarkers, and which have the capacity to target EVs derived from specific cell populations, including EVs derived from Mtb-infected phagocytes and other cell populations involved in granuloma formation. Candidate biomarkers identified will be analyzed using these platforms and correlated with changes in specific granuloma and systemic cell populations.

00:00

George AlexandrakisKeynote Presentation

Plasmonic Nanopore Sensing with Multi-Frequency Burst and Continuous AC Modulation
George Alexandrakis, Professor, Bioengineering Department, University of Texas at Arlington, United States of America

The use of plasmonic nanopores for single molecule detection has attracted considerable attention due to their high sensitivity and selectivity. I will present my group’s work on a phase analysis approach for characterizing the trapping of single molecules in a plasmonic nanopore using trains of multi-frequency AC bursts or continuous AC modulation. By analyzing the phase response of the plasmonic nanopore at select frequencies, we can differentiate between a test ligand, the antibody targeting this ligand, and the complexes that these ligands form, as well as observe their dynamics while inside the optical trap of the plasmonic nanopore. This work shows the feasibility of these two new approaches for rapid and accurate identification of single molecules in complex mixtures.

00:00

Shannon StottKeynote Presentation

Title to be Confirmed
Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School, United States of America

00:00

Brian CunninghamKeynote Presentation

Title to be Confirmed.
Brian Cunningham, Professor and Intel Alumni Endowed Chair, University of Illinois at Urbana-Champaign, United States of America

00:00

Mehmet TonerPlenary Presentation

Title to be Confirmed.
Mehmet Toner, Helen Andrus Benedict Professor of Biomedical Engineering, Massachusetts General Hospital (MGH), Harvard Medical School, and Harvard-MIT Division of Health Sciences and Technology, United States of America

00:00

Andrew GodwinKeynote Presentation

Title to be Confirmed.
Andrew Godwin, Professor and Division Director, Genomic Diagnostics, Founding Director, Kansas Institute for Precision Medicine, Deputy Director, KU Cancer Center, University of Kansas Medical Center, United States of America

00:00

Steve SoperConference Chair

Welcome and Introduction by Conference Chairperson
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine, The University of Kansas, United States of America

00:00

David WongKeynote Presentation

Saliva EFIRM Liquid Biopsy
David Wong, Felix and Mildred Yip Endowed Chair in Dentistry; Director for UCLA Center for Oral/Head & Neck Oncology Research, University of California-Los Angeles, United States of America

Circulating free DNA (ctDNA) liquid biopsy is rapidly emerging to address the unmet clinical need to detect signature mutations in human cancer based on cell-free circulating tumor DNA (ctDNA) as a surrogate for the tumor genome. The detection of ctDNA via liquid biopsy will facilitate analysis of tumor genomics needed for early detection, molecular targeted therapy, treatment monitoring, onset of acquired resistance mutations, recurrence and minimal residual diseases. Currently, most liquid biopsy approaches are plasma-based using PCR and/or next generation sequencing (NGS) with performance concordance in the 60-70% range compared with biopsy-based genotyping. The exciting horizon ctDNA liquid biopsy is hampered by low copy number of ctDNA, volume requirement for assays and sensitivity of detection platform. Saliva is a bodily fluid that we produce ~600ml per day and harbors multiple omics constituents, including ctDNA that can be harnessed non-invasive for personalized and precision medicine applications, is ideal for ctDNA liquid biopsy. Yet conventional PCR-based technologies cannot detect ctDNA in saliva samples whereas an emerging liquid biopsy platform “Electric Field Induced Release and Measurement (EFIRM)” consistently detect ctDNA from NSCLC patients with actionable mutations in plasma and saliva with concordance of 95%+ with tissue/biopsy-based genotyping including early-stage lesions. EFIRM provides the most accurate targeted detection that can assist clinical treatment decisions for non-small cell lung cancer (NSCLC), with tyrosine kinase inhibitors (TKI) that can extend the disease progress free survival period of these patients. The mechanism of EFIRM for ctDNA detection was recently revealed to detect ctDNA that are ~45 bp single-stranded ctDNA we termed ultra-short ctDNA (usctDNA), whereas the conventional ctDNA are mononucleosomal that are ~160 bp and double-stranded. Conventional ddPCR or NGS cannot detect usctDNAs, where a minimum of 78-bp is needed for amplification. Custom design of ddPCR assay to quantify the EGFR L858R usctDNA in saliva of NSCLC patients revealed that the usctDNA is present at high abundance, mean= 62,636; SD ± 63,334, range: 16,500 to 56,375 copies per mL of saliva, permitting its detection in small saliva volume of 50uL or less, directly without sample processing. These results led to the conclusion that there is an emerging landscape of usctDNA that is present at much higher stoichiometry than mononucleosomal ctDNA permitting detection by the EFIRM technology in micro-litter volume of saliva samples, directly without processing, presenting a new frontier for ctDNA liquid biopsy, addressing the low copy number and limit of detection bottleneck of mnctDNA liquid biopsy.

00:00

Yong ZengKeynote Presentation

Title to be Confirmed.
Yong Zeng, Associate Professor, University of Florida, United States of America

00:00

Mei HeKeynote Presentation

Title to be Confirmed.
Mei He, Associate Professor, University of Florida, United States of America

00:00

Sunitha NagrathKeynote Presentation

Title to be Confirmed.
Sunitha Nagrath, Professor of Chemical Engineering and Biomedical Engineering, University of Michigan-Ann Arbor, United States of America

00:00

Title to be Confirmed.
Hyungsoon Im, Associate Professor, Center for Systems Biology, Mass General Hospital (MGH)/Harvard Medical School, United States of America

00:00

David IssadoreKeynote Presentation

Title to be Confirmed.
David Issadore, Professor, University of Pennsylvania, United States of America

00:00

Danilo TagleKeynote Presentation

Title to be Confirmed.
Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

00:00

Adam HallKeynote Presentation

Title to be Confirmed
Adam Hall, Associate Professor of Biomedical Engineering, Wake Forest School of Medicine, United States of America


Agenda is not currently available
Add to Calendar ▼2024-09-26 00:00:002024-09-27 00:00:00Europe/LondonEmerging Technologies for Diagnostics and Liquid Biopsies - New Orleans 2024Emerging Technologies for Diagnostics and Liquid Biopsies - New Orleans 2024 in New OrleansNew OrleansSELECTBIOenquiries@selectbiosciences.com